Immunopathogenetic Role of Anti-Neural Antibodies in Demyelinating Dysimmune Neuropathies

  • E. Nobile-Orazio
  • M. Carpo
Part of the Topics in Neuroscience book series (TOPNEURO)


Since the original reports by Latov et al. [1] of a patient with a demyelinating neuropathy and IgM antibodies to the myelin-associated glycoprotein [2], antibodies to several other neural antigens have been reported in patients with different forms of dysimmune neuropathies (Table 1). The identification of these reactivities in patients with definite neuropathy syndromes did not only introduce a useful tool in the diagnosis of neuropathies but also cast new light on the immunopathogenetic mechanisms involved. In this chapter, we review evidence supporting possible pathogenetic roles for some of the frequently reported antibody reactivities in demyelinating neuropathies.


Motor Neuron Disease Multifocal Motor Neuropathy Myelin Lamella Multifocal Motor Neuropathy Patient Dysimmune Neuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Latov N, Sherman WH, Nemni R et al. (1980) Plasma cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral nerve myelin. N Eng J Med 303: 618–621CrossRefGoogle Scholar
  2. 2.
    Latov N, Hays AP, Sherman WH (1988) Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol 3: 301–332PubMedGoogle Scholar
  3. 3.
    Quarles RH (1989) Myelin-associated glycoprotein in demyelinating disorders. Crit Rev Neurobiol 5: 1–28PubMedGoogle Scholar
  4. 4.
    Trapp BD (1990) Myelin-associated glycoprotein. Location and potential functions. Ann N Y Acad Sci 605: 29–43PubMedCrossRefGoogle Scholar
  5. 5.
    Murray N, Page N, Steck AJ (1986) The human anti-myelin-associated glycoprotein IgM system. Ann Neurol 19: 473–478PubMedCrossRefGoogle Scholar
  6. 6.
    Nobile-Orazio E, Marmiroli P, Baldini L et al. (1987) Peripheral neuropathy in macroglobulinemia: Incidence and antigen specificity of M-proteins. Neurology 37:1506–1514PubMedCrossRefGoogle Scholar
  7. 7.
    Nobile-Orazio E, Francomano E, Daverio R et al. (1989) Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia. Ann Neurol 26: 543–550PubMedCrossRefGoogle Scholar
  8. 8.
    Nobile-Orazio E, Manfredini E, Carpo M et al. (1994) Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 36: 416–424PubMedCrossRefGoogle Scholar
  9. 9.
    McGarry RC, Helfand SL, Quarles RH, Roder JC (1983) Recognition of myelin-associated glycoprotein by the monoclonal antibody HNK-1. Nature 306: 376–378PubMedCrossRefGoogle Scholar
  10. 10.
    Bollensen E, Steck AJ, Schachner M (1988) Reactivity with the peripheral myelin glycoprotein P0 in serum from patients with monoclonal IgM gammopathy and polyneuropathy. Neurology 38:1266–1270PubMedCrossRefGoogle Scholar
  11. 11.
    Snipes GJ, Suter U, Shooter EM (1993) Human peripheral myelin protein-22 carries the L2/HNK1 carbohydrate adhesion epitope. J Neurochem 61:1961–1964PubMedCrossRefGoogle Scholar
  12. 12.
    Chou DKH, Ilyas AA, Evans JE et al. (1986) Structure of sulfated glucuronyl glycolipids in the nervous system reacting with HNK-1 antibody and some IgM paraproteins in neuropathy. J Biol Chem 261: 11717–11725PubMedGoogle Scholar
  13. 13.
    Baldini L, Nobile-Orazio E, Guffanti A et al. (1994) Peripheral neuropathy in IgM monoclonal gammopathy and Waldenstrom macroglobulinemia: A frequent complication in males with low MAG-reactive serum monoclonal component. Am J Hematol 45:25–31PubMedCrossRefGoogle Scholar
  14. 14.
    Nobile-Orazio E (1998) Neuropathies associated with anti-MAG antibodies and IgM monoclonal gammopathies. In: Latov N, Wokke JHJ, Kelly JJ (eds) Immunological and infectious diseases of the peripheral nerve. Cambridge University, Cambridge, pp 169–189Google Scholar
  15. 15.
    Meucci N, Baldini L, Barbieri S et al. (1997) Anti-MAG IgM antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy. Neurology 48(Suppl 2): A52Google Scholar
  16. 16.
    Nobile-Orazio E, Latov N, Hays AP et al. (1984) Neuropathy and anti-MAG antibodies without detectable serum M-protein. Neurology 34: 218–221PubMedCrossRefGoogle Scholar
  17. 17.
    Gosselin S, Kyle RA, Dyck PJ (1991) Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol 30: 54–61PubMedCrossRefGoogle Scholar
  18. 18.
    Ilyas A A, Chou DKH, Jungalwala FB et al. (1990) Variability in the structural requirement for binding of human monoclonal anti-myelin-associated glycoprotein immunoglobulin M antibodies and HNK-1 to sphingolipid antigens. J Neurochem 55: 594–601PubMedCrossRefGoogle Scholar
  19. 19.
    Lieberman F, Marton LS, Stefansson K (1985) Pattern of reactivity of IgM from the sera of eight patients with IgM monoclonal gammopathy and neuropathy with components of neural tissues: evidence for interaction with more than one epitope. Acta Neuropathol (Berl) 68:196–200CrossRefGoogle Scholar
  20. 20.
    Ogino M, Tatum AH, Latov N (1994) Affinity of human anti-MAG antibodies in neuropathy. J Neuroimmunol 52:41–46PubMedCrossRefGoogle Scholar
  21. 21.
    Smith IS (1994) The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinemia. Brain 117: 949–957PubMedCrossRefGoogle Scholar
  22. 22.
    Nobile-Orazio E, Meucci N, Baldini L et al. (1997) Long-term prognosis of neuropathy associated with anti-MAG IgM. J Neurol 244(Suppl. 3): S41Google Scholar
  23. 23.
    Kaku DA, England JD, Sumner AJ (1994) Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 117:941–947PubMedCrossRefGoogle Scholar
  24. 24.
    Meier C, Vandevelde M, Steck A, Zurbriggen A (1983) Demyelinating polyneuropathy associated with monoclonal IgM paraproteinemia. Histological, ultra-structural and immunocytochemical studies. J Neurol Sci 63: 353–367CrossRefGoogle Scholar
  25. 25.
    Nemni R, Galassi G, Latov N et al. (1983) Polyneuropathy in nonmalignant IgM plasma cell dyscrasia: a morphological study. Ann Neurol 14: 43–54PubMedCrossRefGoogle Scholar
  26. 26.
    Vital A, Vital C, Julien J et al. (1989) Polyneuropathy associated with IgM monoclonal gammopathy. Immunological and pathological study in 31 patients. Acta Neuropathol 79:160–167PubMedCrossRefGoogle Scholar
  27. 27.
    Takatsu M, Hays AP, Latov N et al. (1985) Immunofluorescence study of patients with neuropathy and IgM M-proteins. Ann Neurol 18:173–181PubMedCrossRefGoogle Scholar
  28. 28.
    Hays AP, Lee SSL, Latov N (1988) Immune reactive C3d on the surface of myelin sheaths in neuropathy. J Neuroimmunol 18: 231–244PubMedCrossRefGoogle Scholar
  29. 29.
    Monaco S, Bonetti B, Ferrari S et al. (1990) Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. New Eng J Med 322:649–652PubMedCrossRefGoogle Scholar
  30. 30.
    Ernerudh JH, Vrethem M, Andersen O et al. (1992) Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy. J Neurol Neurosurg Psychiatry 55: 930–934PubMedCrossRefGoogle Scholar
  31. 31.
    Melmed C, Frail D, Duncan I et al. (1983) Peripheral neuropathy with IgM monoclonal immunoglobulin directed against myelin-associated glycoprotein. Neurology 33:1397–1405PubMedCrossRefGoogle Scholar
  32. 32.
    Stefansson K, Marton L, Antel JP et al. (1983) Neuropathy accompanying IgM lambda monoclonal gammopathy. Acta Neuropathol (Berl) 59: 255–261CrossRefGoogle Scholar
  33. 33.
    Blume G, Pestronk A, Goodnough LT (1995) Anti-MAG antibodies associated polyneuropathies: Improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology 45:1577–1580PubMedCrossRefGoogle Scholar
  34. 34.
    Kelly JJ, Adelman LS, Berkman E, Bhan I (1988) Polyneuropathies associated with IgM monoclonal gammopathies. Arch Neurol 45: 1355–1359.PubMedCrossRefGoogle Scholar
  35. 35.
    Nobile-Orazio E, Baldini L, Barbieri S et al. (1988) Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol 24: 93–97PubMedCrossRefGoogle Scholar
  36. 36.
    Hays AP, Latov N, Takatsu M, Shermann WH (1987) Experimental demyelination of nerve induced by serum of patients with neuropathy and anti-MAG IgM M-proteins. Neurology 37: 242–256PubMedCrossRefGoogle Scholar
  37. 37.
    Willison HJ, Trapp BD, Bacher JD et al. (1988) Demyelination induced by intraneural injection of human anti-myelin-associated glycoprotein antibodies. Muscle Nerve 11:1169–1176PubMedCrossRefGoogle Scholar
  38. 38.
    Tatum AH (1993) Experimental paraprotein neuropathy; demyelination by passive transfer of human anti-myelin-associated glycoprotein. Ann Neurol 33: 502–506PubMedCrossRefGoogle Scholar
  39. 39.
    Monaco S, Ferrari S, Bonetti B et al. (1995) Experimental induction of myelin changes by anti-MAG antibodies and terminal complement complex. J Neuropathol Exp Neurol 54: 96–104PubMedCrossRefGoogle Scholar
  40. 40.
    Lee KW, Inghirami G, Sadiq SA et al. (1990) B-cells that secrete anti-MAG or anti-GMl antibodies are present at birth and anti-MAG secreting B-cells are CD5+. Neurology 40(Suppl 1):367CrossRefGoogle Scholar
  41. 41.
    Dighiero G, Lymberi P, Guilbert B et al. (1986) Natural autoantibodies constitute a substantial part of normal circulating immunoglobulins. Ann N Y Acad Sci 475:135–145PubMedCrossRefGoogle Scholar
  42. 42.
    Avrameas S, Guilbert B, Dighiero B (1981) Natural antibodies against tubulin, actin, myoglobulin, thyroglobulin, fetuin and transferrin are present in normal human sera and monoclonal immunoglobulins from multiple myeloma and Waldenstrom macroglobulinemia may express similar antibody specificities. Ann Immunol 132C: 103–113Google Scholar
  43. 43.
    Latov N (1987) Waldenstrôm’s macroglobulinemia and nonmalignant IgM monoclonal gammopathies. In: Kelly JJ, Kyle RA, Latov N (eds) Polyneuropathies associated with plasma cell dyscrasia. Martinus Nijhoff, Boston, pp 51–72CrossRefGoogle Scholar
  44. 44.
    Latov N, Godfrey M, Thomas Y et al. (1985) Neuropathy and anti-myelin-associated glycoprotein IgM M-proteins: T cell regulation of M-protein secretion in vitro. Ann Neurol 18:182–188PubMedCrossRefGoogle Scholar
  45. 45.
    Spatz L, Latov N (1986) Secretion of anti-myelin associated glycoprotein antibodies by B-cells from patients with neuropathy and nonmalignant monoclonal gammopathy. Cell Immunol 1: 434–440CrossRefGoogle Scholar
  46. 46.
    Nobile-Orazio E, Mcintosh C, Latov N (1985) Anti-MAG antibody and antibody complexes: Detection by radioimmunoassay. Neurology 35: 988–992PubMedCrossRefGoogle Scholar
  47. 47.
    Page N, Murray N, Perruisseau G, Steck AJ (1985). A monoclonal anti-idiotypic antibody against a human monoclonal IgM with specificity for myelin-associated glycoprotein. J Immunol 134: 3094–3099PubMedGoogle Scholar
  48. 48.
    Tanaka M, Nishizawa M, Inuzuka T et al. (1985) Human natural killer cell activity is reduced by treatment of anti-myelin-associated glycoprotein (MAG) monoclonal mouse IgM antibody and complement. J Neuroimmunol 10:115–127PubMedCrossRefGoogle Scholar
  49. 49.
    Svennerholm L, Fredman P (1990) Antibody detection in Guillain Barre’ syndrome. Ann Neurol 27(Suppl): 36–40CrossRefGoogle Scholar
  50. 50.
    Pestronk A, Li F, Griffin J, Feldman EL, Cornblath D, Trotter J, Zhu S, Yee WC, Phillips D, Peeples DM, Winslow B (1991) Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology 41: 357–362PubMedCrossRefGoogle Scholar
  51. 51.
    Quattrini A, Corbo M, Dhaliwal SK et al. (1992) Anti-sulfatide antibodies in neurological disease: Binding to rat dorsal root ganglia neurons. J Neurol Sci 112:152–159PubMedCrossRefGoogle Scholar
  52. 52.
    Nemni R, Fazio R, Quattrini A et al. (1993) Antibodies to sulfatide and to chondroitin sulfate C in patients with chronic sensory neuropathy. J Neuroimmunol 43: 79–86PubMedCrossRefGoogle Scholar
  53. 53.
    van den Berg LH, Lankamp CLAM, de Jager AEJ et al. (1993) Anti-sulphatide antibodies in peripheral neuropathy. J Neurol Neurosurg Psychiatry 56: 1164–1168PubMedCrossRefGoogle Scholar
  54. 54.
    Lopate G, Parks BJ, Goldstein JM et al. (1997) Polyneuropathies associated with high titre antisulphatide antibodies: Characteristics of patients with and without monoclonal proteins. J Neurol Neurosurg Psychiatry 62: 581–585PubMedCrossRefGoogle Scholar
  55. 55.
    Ferrari S, Morbin M, Nobile-Orazio E et al. (1998) Antisulfatide polyneuropathy: Antibody-mediated complement attack on peripheral myelin. Acta Neuropathol (in press)Google Scholar
  56. 56.
    Wiegandt H (1985) Gangliosides. In: Wiegandt H (ed) Glycolipids. Elsevier, Amsterdam, pp 199–260CrossRefGoogle Scholar
  57. 57.
    Freddo L, Yu RK, Latov N et al. (1986) Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease. Neurology 36: 454–458PubMedCrossRefGoogle Scholar
  58. 58.
    Pestronk A, Cornblath DR, Ilyas A et al. (1988) A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 24: 73–78PubMedCrossRefGoogle Scholar
  59. 59.
    Lange DJ, Trojaburg W, Latov N et al. (1992) Multifocal motor neuropathy with conduction block: Is it a distinct clinical entity? Neurology 42: 497–505PubMedCrossRefGoogle Scholar
  60. 60.
    Pestronk A, Choksi R (1997) Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology 49:1289–1292PubMedCrossRefGoogle Scholar
  61. 61.
    Lamb NL, Patten BM (1991) Clinical correlations of anti-GM1 antibodies in amyotrophic lateral sclerosis and neuropathies. Muscle Nerve 14:1021–1027PubMedCrossRefGoogle Scholar
  62. 62.
    Sadiq SA, Thomas FP, Kilidireas K et al. (1990) The spectrum of neurological disease associated with anti-GM1 antibodies. Neurology 40:1067–1072PubMedCrossRefGoogle Scholar
  63. 63.
    Kinsella LJ, Lange DJ, Trojaburg W et al. (1994) Clinical and electrophysiologic correlates of elevated anti-GM1 antibody titers. Neurology 44: 1278–1282PubMedCrossRefGoogle Scholar
  64. 64.
    Kornberg AJ, Pestronk A (1994) The clinical and diagnostic role of anti-GM1 antibody testing. Muscle Nerve 17:100–104PubMedCrossRefGoogle Scholar
  65. 65.
    Nobile-Orazio E, Legname G, Daverio R et al. (1990) Motor neuron disease in a patient with a monoclonal IgMk directed against GM1, GD1b and high-molecular-weight neural-specific glycoproteins. Ann Neurol 28:190–194PubMedCrossRefGoogle Scholar
  66. 66.
    van Schaik IN, Bossuyt PMM, Brand A, Vermeulen M (1995) Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: A meta analysis. Neurology 45: 1570–1577PubMedCrossRefGoogle Scholar
  67. 67.
    Nobile-Orazio E (1996) Multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 60: 599–603PubMedCrossRefGoogle Scholar
  68. 68.
    Willison H J (1994) Antiglycolipid antibodies in peripheral neuropathy: Fact or fiction. J Neurol Neurosurg Psychiatry 57: 1303–1307PubMedCrossRefGoogle Scholar
  69. 69.
    Feldman EL, Bromberg MB, Albers JW, Pestronk A (1991) Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 30: 397–401PubMedCrossRefGoogle Scholar
  70. 70.
    Azulay JP, Blin O, Pouget J et al. (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies. Neurology 44: 429–432PubMedCrossRefGoogle Scholar
  71. 71.
    Bouche P, Moulonguet A, Younes-Chennoufi AB et al. (1995) Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 59:38–44PubMedCrossRefGoogle Scholar
  72. 72.
    Chaudhry V, Corse A, Cornblath DR et al. (1993) Multifocal motor neuropathy: Response to human immune globulin. Ann Neurol 33: 237–242PubMedCrossRefGoogle Scholar
  73. 73.
    Nobile-Orazio E, Meucci N, Barbieri S et al. (1993) High dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 43: 537–544PubMedCrossRefGoogle Scholar
  74. 74.
    Santoro M, Thomas FP, Fink ME et al. (1990) IgM deposits at the node of Ranvier in a patient with amyotrophic lateral sclerosis, anti-GM1 antibodies and multifocal conduction block. Ann Neurol 28: 373–377PubMedCrossRefGoogle Scholar
  75. 75.
    Santoro M, Uncini A, Corbo M et al. (1992) Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol 31: 385–390PubMedCrossRefGoogle Scholar
  76. 76.
    Uncini A, Santoro M, Corbo M et al. (1993) Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve 16: 610–615PubMedCrossRefGoogle Scholar
  77. 77.
    Arasaki K, Kusunoki S, Kudo N, Kanazawa I (1993) Acute conduction block in vitro following exposure to anti-ganglioside sera. Muscle Nerve 16: 587–593PubMedCrossRefGoogle Scholar
  78. 78.
    Harvey GK, Toyka KV, Zielasek J et al. (1995) Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer. Muscle Nerve 18: 388–394PubMedCrossRefGoogle Scholar
  79. 79.
    Roberts M, Willison HJ, Vincent A, Newsom-Davis J (1995) Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol 38:111–118PubMedCrossRefGoogle Scholar
  80. 80.
    Enders U, Karch H, Toyka KV et al. (1993) The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol 34:136–144PubMedCrossRefGoogle Scholar
  81. 81.
    Yuki N, Yoshino H, Sato S Miyatake T (1990) Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 40:1900–1902PubMedCrossRefGoogle Scholar
  82. 82.
    Walsh FS, Cronin M, Koblar S, Doherty P et al. (1991) Association between glycocon-jugate antibodies and Campylobacter infection in patients with Guillain Barre’ syndrome. J Neuroimmunol 34: 43–51PubMedCrossRefGoogle Scholar
  83. 83.
    Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL (1993) Serum antibodies to GM1.GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barre’ syndrome and controls: Correlation and prognosis. Ann Neurol 34:130–135PubMedCrossRefGoogle Scholar
  84. 84.
    Nobile-Orazio E, Carpo M, Meucci N et al. (1992) Guillain Barre’ syndrome associated with high titers of anti-GM1 antibodies. J Neurol Sci 109: 200–206PubMedCrossRefGoogle Scholar
  85. 85.
    Rees JH, Gregson NA, Hughes RAC (1995) Anti-ganglioside GM1 antibodies in Guillain Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 38: 809–816PubMedCrossRefGoogle Scholar
  86. 86.
    Chiba A, Kusunoki S, Shimizu T, Kanazawa I (1992) Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 31: 677–679PubMedCrossRefGoogle Scholar
  87. 87.
    Chiba A, Kusuno ki S, Obata H et al. (1993) Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: Clinical and immunohistochemical studies. Neurology 43:1911–1917PubMedCrossRefGoogle Scholar
  88. 88.
    Yuki N, Sato S, Tsuji S et al. (1993) Frequent presence of anti-GQ1b antibody in Fisher’s syndrome. Neurology 43: 414–417PubMedCrossRefGoogle Scholar
  89. 89.
    Carpo M, Pedotti R, Lolli F et al. (1998) Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy. J Neurol Sci 155: 186–191PubMedCrossRefGoogle Scholar
  90. 90.
    Yuki N, Sato S, Tsuji S et al. (1993) An immunological abnormality common to Bickerstaff’s encephalitis and Fisher’s syndrome. J Neurol Sci 118: 83–87PubMedCrossRefGoogle Scholar
  91. 91.
    Yuki N (1996) Acute paresis of extraocular muscles associated with IgG anti-GQ1b antibody. Ann Neurol 39: 668–672PubMedCrossRefGoogle Scholar
  92. 92.
    Ropper AH (1992) The Guillain Barré syndrome. N Eng J Med 326:1130–1136CrossRefGoogle Scholar
  93. 93.
    Yuki N, Miyatake T, Ohsawa T (1993) Beneficial effect of plasmapheresis on Fisher’s syndrome. Muscle Nerve 16: 1267–1268PubMedCrossRefGoogle Scholar
  94. 94.
    Yuki N (1995) Successful plasmapheresis in Bickerstaff’s brain stem encephalitis associated with anti-GQ1b antibody. J Neurol Sci 131:108–110PubMedCrossRefGoogle Scholar
  95. 95.
    Roberts M, Willison H, Vincent A, Newsom-Davis I (1994) Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. Lancet 343: 454–455PubMedCrossRefGoogle Scholar
  96. 96.
    Buchwald B, Wiishaupt A, Toyka KV, Dudel J (1995) Immunoglobulin G from a patient with Miller-Fisher syndrome rapidly and reversibly decrease evoked quantal release at the neuromuscular junction in mice. Neurosci Lett 201: 163–166PubMedCrossRefGoogle Scholar
  97. 97.
    Ilyas AA, Quarles RH, Dalakas MC et al. (1985) Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to a carbohydrate containing disialosy) groups. Ann Neurol 18: 655–659PubMedCrossRefGoogle Scholar
  98. 98.
    Obi T, Kusunoki S, Takatsu M et al. (1992) IgM M-protein in a patient with sensory dominant neuropathy binds preferentially to polysialogangliosides. Acta Neurol Scand 86: 215–218PubMedCrossRefGoogle Scholar
  99. 99.
    Daune GC, Farrer RG, Dalakas MC, Quarles RH (1992) Sensory neuropathy associated with monoclonal immunoglobulin M to GD1b ganglioside. Ann Neurol 31:683–685PubMedCrossRefGoogle Scholar
  100. 100.
    Willison HJ, Paterson G, Veitch J et al. (1993) Peripheral neuropathy associated with monoclonal IgM anti-Pr2 cold agglutinins. J Neurol Neurosurg Psychiatry 56:1178–1183PubMedCrossRefGoogle Scholar
  101. 101.
    Oka N, Kusaka H, Kusunoki S et al. (1996) IgM M-protein with antibody activity against gangliosides with disialosyl residue in sensory neuropathy binds to sensory neurons. Muscle Nerve 19: 528–530PubMedCrossRefGoogle Scholar
  102. 102.
    Yuki N, Miyatani N, Sato S et al. (1992) Acute relapsing sensory neuropathy associated with IgM antibody against B-series gangliosides containing GalNacβ1-4 (Gal3-2αNeuAc8-2ocNeuAc)β1 configuration. Neurology 42: 686–689PubMedCrossRefGoogle Scholar
  103. 103.
    Yuki N, Yamada M, Sato S et al. (1993) Association of IgG anti-GD1a antibody with severe Guillain-Barre’ syndrome. Muscle Nerve 16: 642–647PubMedCrossRefGoogle Scholar
  104. 104.
    Carpo M, Nobile-Orazio E, Meucci N et al. (1996) Anti-GD1a ganglioside antibodies in peripheral motor syndromes. Ann Neurol 39: 539–543PubMedCrossRefGoogle Scholar
  105. 105.
    Bollensen E, Schipper HI, Steck AJ (1989) Motor neuropathy with activity of monoclonal IgM antibody to GD1a ganglioside. J Neurol 236: 353–355PubMedCrossRefGoogle Scholar
  106. 106.
    Ilyas AA, Li SC, Chou DKH et al. (1988) Gangliosides GM2, IVGalNAcGM1b, and IVGalNAcGD1a as antigens for monoclonal immunoglobulin M in neuropathy associated with gammopathy. J Biol Chem 263: 4369–4373PubMedGoogle Scholar
  107. 107.
    Irie S, Saito T, Nakamura K et al. (1996) Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J Neuroimmuno 168: 19–26CrossRefGoogle Scholar
  108. 108.
    Sherman WH, Latov N, Hays AP et al. (1983) Monoclonal IgM-k antibody precipitating with chondroitin sulphate C from patients with axonal polyneuropathy and epidermolysis. Neurology 33:192–201PubMedCrossRefGoogle Scholar
  109. 109.
    Connolly AM, Pestronk A, Trotter JL et al. (1993) High titer selective serum anti-β-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. Neurology 43: 557–562PubMedCrossRefGoogle Scholar
  110. 110.
    Graus F, Cordon-Cardo C, Posner JB (1985) Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology 35: 538–543PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1999

Authors and Affiliations

  • E. Nobile-Orazio
    • 1
  • M. Carpo
    • 1
  1. 1.Giorgio Spagnol Service of Clinical Neuroimmunology, Centro Dino Ferrari, Institute of Clinical Neurology, IRCCS Ospedale Maggiore PoliclinicoUniversity of MilanMilanItaly

Personalised recommendations